Biomedical subjects

Imran Ahmed

Publications and source records attributed to Imran Ahmed.

3 recordsLinked to original sources

PubMed2006

Multimodal management, including precisely targeted irradiation, in a severe refractory case of Evans syndrome.

A challenging case of acute autoimmune thrombocytopenia (ITP) which evolved into a chronic refractory case of Evans syndrome over a period of more than 23 years is presented and may illustrate current therapeutic dilemmas now perplexing patients and clinicians. Newer modalities are being developed and their eventual role in the scheme of clinical management remains to be established. While this development unfolds, highly targeted radiotherapy was applied in this case to reduce platelet uptake by a refractory recurrent splenule with the goal of stabilizing the platelet count until promising investigational thrombopoietic agents or other newer, less toxic therapies might become available for wider application.

Adult↗

PubMed2002

Pharmaceutical challenges in veterinary product development.

There are many similarities between the human health and animal health industries. Both industries are research driven, have global presence, are highly regulated, and have to profit in a competitive business environment. However, there are also notable differences. This review highlights and discusses those differences as they relate to the pharmaceutical challenges in veterinary product development. This paper provides a brief review of the animal health pharmaceutical product landscape, segmentation, and market evolution; highlights challenges and special considerations in veterinary drug delivery; and identifies unmet needs in animal health along with recent advances.

Animals↗

PubMed2002

Gemcitabine-induced pulmonary toxicity: case report and review of the literature.

Gemcitabine is a pyrimidine analog with a similar chemical structure and mechanism of action, as cytarabine. It has been shown to be a highly active agent for non-small cell lung cancer, pancreatic cancer, urothelial cancer, breast cancer and ovarian cancer. Gemcitabine is relatively well tolerated and myelosuppression is the dose-limiting toxicity. Pulmonary toxicity with gemcitabine is relatively uncommon, but a well recognized entity, associated with significant morbidity and mortality. A high index of suspicion, early diagnosis and timely intervention with oxygen supplementation, steroids, and diuretics is necessary to manage patients with this complication.

Aged↗